FDA Wants Input on Tobacco Violations Reporting Form
Published Date: 6/23/2026
Notice
Summary
The FDA wants your thoughts on a new form to report possible tobacco product rule-breakers. This affects anyone who might spot tobacco violations and helps the FDA keep products safe. You’ve got until August 24, 2026, to share your comments—no cost to you, just your voice!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
New Tobacco Violation Report Form
You can report possible tobacco product violations to the FDA using Form FDA 3779 (Potential Tobacco Product Violations Report). FDA estimates 3,000 respondents will submit a total of 6,000 reports per year, with each report taking about 0.25 hours (15 minutes) to complete, for an estimated 1,500 total burden hours annually; FDA states there are no capital or operating costs. The agency is also asking for public comments on this information collection by August 24, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12579 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification of Identity, Form FDA 3975
The FDA is asking for approval to keep using Form FDA 3975, which helps confirm who you are when you ask for your own records under the Freedom of Information Act or Privacy Act. If you want your personal info from the FDA but didn’t prove your identity well enough, this form steps in. Comments on this plan are open until July 23, 2026, and there’s no new cost for you—just a smoother way to get your info!
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
Previous / Next Documents
Previous: 2026-12575 — Foreign-Trade Zone (FTZ) 189; Authorization of Production Activity; Plascore, Incorporated; (Metal, Aramid Paper and Plastic Honeycomb); Zeeland, Michigan
Plascore, Incorporated in Zeeland, Michigan, got the green light to make metal, aramid paper, and plastic honeycomb products in Foreign-Trade Zone 189. This approval lasts two years and helps Plascore find a local supplier for aramid fiber. The move could speed up production and save money by using special trade zone benefits.
Next: 2026-12579 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification of Identity, Form FDA 3975
The FDA is asking for approval to keep using Form FDA 3975, which helps confirm who you are when you ask for your own records under the Freedom of Information Act or Privacy Act. If you want your personal info from the FDA but didn’t prove your identity well enough, this form steps in. Comments on this plan are open until July 23, 2026, and there’s no new cost for you—just a smoother way to get your info!